WDC
55
-2
EL
34
-16
SHW
46
3
MPC
39
-2
DO
54
2
INTU
65
-2
ALL
53
3
GOOG
87
4
MUR
44
-3
MET
43
6
PRU
54
7
PX
19
3
L
55
5
HRL
36
-2
HPE
10
-6
AMGN
55
5
LUV
48
-2
AMT
56
5
SYY
48
-2
XOM
48
-3
WDC
55
-2
EL
34
-16
SHW
46
3
MPC
39
-2
DO
54
2
INTU
65
-2
ALL
53
3
GOOG
87
4
MUR
44
-3
MET
43
6
PRU
54
7
PX
19
3
L
55
5
HRL
36
-2
HPE
10
-6
AMGN
55
5
LUV
48
-2
AMT
56
5
SYY
48
-2
XOM
48
-3
Financhill
Back

Supernus Pharmaceuticals 10K Form

Sell
38

SUPN
Supernus Pharmaceuticals

Last Price:
30.09
Seasonality Move:
12.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q SUPN/Supernus Pharmaceuticals Quarterly
2023-08-08 10Q SUPN/Supernus Pharmaceuticals Quarterly
2023-05-09 10Q SUPN/Supernus Pharmaceuticals Quarterly
2022-11-09 10Q SUPN/Supernus Pharmaceuticals Quarterly
2022-08-08 10Q SUPN/Supernus Pharmaceuticals Quarterly
2022-05-12 10Q SUPN/Supernus Pharmaceuticals Quarterly

Receive SUPN News And Ratings

See the #1 stock for the next 7 days that we like better than SUPN

SUPN Financial Statistics

Sales & Book Value

Annual Sales: $607.52M
Cash Flow: $44.99M
Price / Cash Flow: 15.42
Annual Sales: $16.84
Price / Book: 1.79

Profitability

EPS (TTM): -0.00260
Net Income (TTM): $1.32M
Gross Margin: $523.74M
Return on Equity: 0.15%
Return on Assets: 0.09%

Supernus Pharmaceuticals Earnings Forecast

Key Supernus Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 15 years for SUPN is 86.21%.
  • The Selling, General & Administrative Expenses for SUPN have been equal to 55.37% of Gross Profit Margin.
  • The Research & Development expenses have been 15.08% of Revenue.
  • The Interest Expense is 183.51% of Operating Income.
  • The Net Earning history of SUPN is 0.22% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 9 years.

Supernus Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: SUPN
CUSIP: 868459
Website: supernus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.7
Quick Ratio: 1.38

Price-to-Earnings

Trailing P/E Ratio: 1503
Forward P/E Ratio: 15.44

SUPN Technical Analysis vs Fundamental Analysis

Sell
38
Supernus Pharmaceuticals (SUPN) is a Sell

Is Supernus Pharmaceuticals a Buy or a Sell?